SUPERNUS PHARMACEUTICALS, INC.
About SUPERNUS PHARMACEUTICALS, INC.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $719.0M
- Net income
- -$38.5M
- Total assets
- $1.5B
- Market cap
- $2.6B
- Gross margin
- 89.6%
- Operating margin
- -8.7%
- Net margin
- -5.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $719.0M
- Cost of revenue
- $74.6M
- Gross profit
- $644.4M
- Operating expenses
- $706.7M
- Operating income
- -$62.3M
- Income tax
- -$10.5M
- Net income
- -$38.5M
- EPS (basic)
- $-0.68
- EPS (diluted)
- $-0.68
Balance sheet
- Total assets
- $1.5B
- Current assets
- $644.2M
- Total liabilities
- $390.9M
- Current liabilities
- $338.2M
- Shareholders’ equity
- $1.1B
Cash flow
- Operating cash flow
- $47.3M
- Investing cash flow
- $4.1M
- Financing cash flow
- $9.1M
- Net cash flow
- $60.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.6B
- EPS (diluted)
- $-0.68
- Shares outstanding
- 58.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 1, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $38.5M in FY2025.
- Revenue grew 38% from FY2020 to FY2025.
- Gross margin of 89.6%, net margin -5.4%.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SUPERNUS PHARMACEUTICALS, INC..
Write a review
News about SUPERNUS PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
